GlassScriptPhysician profile
William A Shade
NPI 1104816321
$2,545.28
in general payments reported to CMS, 2019-2025
35 companies · $529 in 2025
The $529 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $64.85 · 2020: $139 · 2021: $317 · 2022: $335 · 2023: $675 · 2024: $485 · 2025: $529.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,672 · Education: $16.11.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,672.48 |
| Education | $16.11 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,049.49 | 2021-2025 | Ubrelvy, Qulipta, Vraylar |
| Edwards Lifesciences Corporation | $132.72 | 2025 | Edwards Sapien 3 Transcatheter Heart Valve (Thv) |
| Astrazeneca Pharmaceuticals LP | $129.11 | 2020-2025 | Airsupra, Breztri |
| Amgen INC. | $112.97 | 2019-2022 | |
| Exact Sciences Corporation | $108.41 | 2023-2025 | Cologuard Collection Kit |
| Astellas Pharma US INC | $69.68 | 2025 | Veozah |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $66.37 | 2023-2025 | Caplyta |
| Nestle Healthcare Nutrition INC. | $56.10 | 2021-2023 | |
| Novo Nordisk INC | $55.04 | 2023 | Rybelsus, Wegovy |
| Janssen Pharmaceuticals, INC | $54.04 | 2021-2022 | |
| Merck Sharp & Dohme LLC | $50.11 | 2020-2023 | M-M-R II, Gardasil 9, Pneumovax 23 |
| Boston Scientific Corporation | $45.35 | 2023-2025 | Watchman Access System |
| Lilly USA, LLC | $45.06 | 2022-2025 | Kisunla |
| Novartis Pharmaceuticals Corporation | $43.83 | 2021-2023 | |
| Xeris Pharmaceuticals, INC. | $43.45 | 2022-2023 | Gvoke Hypopen |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ethicon INC. | $41.12 | 2023 | Monarch Platform |
| Glaxosmithkline, LLC. | $37.79 | 2024 | Shingrix |
| Dexcom, INC. | $35.36 | 2024-2025 | Dexcom G6 Transmitter |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $30.78 | 2023-2024 | Xifaxan |
| Acadia Pharmaceuticals INC | $30.52 | 2021-2024 | Daybue |
| Amarin Pharma, INC. | $29.07 | 2020 | |
| Sumitomo Pharma America, INC. | $28.62 | 2023-2025 | Gemtesa |
| E.R. Squibb & Sons, L.L.C. | $26.88 | 2022-2023 | Camzyos |
| Pfizer INC. | $26.58 | 2020-2025 | |
| Qol Medical, LLC | $25.90 | 2025 | Sucraid |
| Corcept Therapeutics | $23.71 | 2023 | Korlym |
| Avanir Pharmaceuticals, INC. | $22.00 | 2021 | |
| Otsuka America Pharmaceutical, INC. | $19.75 | 2023 | Rexulti |
| Sun Pharmaceutical Industries INC. | $19.03 | 2021 | |
| Abiomed | $15.72 | 2024 | Impella |
| Ardelyx, INC. | $15.34 | 2024 | Ibsrela |
| Eisai INC. | $15.12 | 2020 | |
| Neurelis, INC. | $14.55 | 2023 | Valtoco |
| Abbott Laboratories | $13.35 | 2021 | |
| Esperion Therapeutics, INC. | $12.36 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw William Shade listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.